3d-printed organs

Houston researchers are commercializing their human tissue-printing technology

Houston researchers are commercializing their organ 3D printing technology. Jordan Miller/Rice University

There may come a time when you or someone you love is in need of a new pair of lungs. Or perhaps it's a liver. It's not a scenario anyone dreams of, but thanks to Houston company Volumetric, you may never end up on a waiting list. Instead, that organ is made to order and 3D printed using a mix of medical plastics and human cells.

And this possibility isn't necessarily in the distant future. On the cover of the May 3 issue of the journal Science, is a contraption that looks a bit like a futuristic beehive. It's a working air sac complete with blood vessels, the beginnings of a technology that is perhaps only a decade from being implanted in humans. And it was crafted on a 3D printer in Jordan Miller's lab at Rice University.

Yes, there are shades of another Houston story — Denton Cooley's implantation of the first artificial heart — but Cooley only inserted the organ. Miller and his bioengineering graduate student Bagrat Grigoryan are primed to profit from their inventions.

In 2018, they started Volumetric Inc., a company that sells both the hydrogel solutions used for printing organs like theirs and the printers themselves. Touring Miller's lab in the Houston Medical Center is a visual timeline of his team's progress designing printers. The version being manufactured is a slick little number, small enough to fit under chemical exhaust hoods, but fitted with everything necessary to print living tissues. It's made and sold in cooperation with CellInk, a larger bioprinting company.

"Our technology is based on projection," Miller explains. Specifically, it's stereolithography, a type of 3D printing that produces the finished product layer-by-layer. Shining colored light of the right intensity turns the polymers into a solid gel.

But why start a company when Miller and Grigoryan are already busy with research?

"If we want to do translational research, commercialization is important," reasons Miller. "We need to build the market to get that technology into the world."

Miller explains that usually the inventor of a technology is the best one to bring it to market.

"When we were building this technology in the lab we saw the potential for commercialization," he recalls. "We do see that this technology is highly scalable. We do think it can have a positive impact on tissue models in a lab."

Those tissue models could one day make not just scientists, but also animal rights activists, very happy. With the technology that Volumetric is developing, scientists could eventually print human cells so well that animal models would be far less accurate in predicting the success that the product being tested would have on humans.

As academics, though, Miller and Grigoryan weren't sure how to start a company. Fortunately, there is the National Science Foundation (NSF) and its I-Corps program. The pair spent a couple of weeks doing a regional program that taught scientists how to commercialize their technology.

"They want to see funded research get out of the lab," Miller says, explaining that they moved on to the national I-Corps program while Miller was on sabbatical from teaching at Rice, allowing them to interview potential customers.

This gave them the confidence to launch last year. Grigoryan now works full-time at the Med Center incubator and accelerator, Johnson & Johnson's JLabs. He has a team of two other scientists on staff.

"It would have been a lot harder to get started if we didn't have a space like JLabs available," Miller says. It also helps, he adds, that JLabs takes no equity, only helping the fledgling brand to finalize its market and get hooked in with potential investors.

Volumetric has its demo units ready to go and expects to start shipping printers in late June, pending final certifications.

"We believe we have technology to make organ replacements for people," Miller says.

And someday soon, long waits for a new set of lungs and a life of antirejection drugs could be a thing of the past.


Rice University bioengineers (from left) Bagrat Grigoryan, Jordan Miller and Daniel Sazer and collaborators created a breakthrough bioprinting technique that could speed development of technology for 3D printing replacement organs and tissues. Photo by Jeff Fitlow/Rice University

Trending News

Building Houston

 
 

Data Gumbo, founded and led by Andrew Bruce, has announced its latest funding. Photo courtesy of Data Gumbo

A Houston-based tech company has announced another round of funding to support its blockchain network growth as well as to establish a presence in the Middle East.

Data Gumbo has closed its series B funding round totaling $7.7 million with follow-on investments led by Equinor Ventures. The round includes participation from Saudi Aramco Energy Ventures and Bay Area and Houston-based venture firm L37. The round's first close was announced in September 2020 at $4 million. The additional funds to close the Series B will be used to scale Data Gumbo to serve demand for GumboNet™ and GumboNet™ ESG. Additionally, Data Gumbo plans to establish a presence in the Middle East to cover expected demand growth in the region.

"The successful close of our series B is continued proof of the efficacy and booming interest in our ability to capture critical cost savings, deliver trust and provide transparency across commercial relationships," says Andrew Bruce, founder and CEO of Data Gumbo, in a news release. "Compounded by the growing demand for transparent, accurate sustainability data and the launch of our automated ESG measurement solution, GumboNet™ ESG, Data Gumbo's trajectory is well-positioned to serve our growing customer base by ensuring economic productivity and value. This infusion of capital will support our expansion efforts as we bring more international users to our network."

With this latest raise, Data Gumbo's total funding raised to date is $18.4 million.

"Data Gumbo's success is marked by a wide variety of business use cases and opportunities for expansion," says Bruce Niven, chief investment officer at Aramco Ventures, in the release. "Our continued investment is a testament to our continued support as the company attracts new customers, experiences further demand for its network and gains traction in new markets."

The company's technology features smart contract automation and execution, which reduces contract leakage, frees up working capital, enables real-time cash and financial management, and delivers provenance with unprecedented speed, accuracy, visibility and transparency, per the release.

"Data Gumbo is the market leader for smart contracts backed by blockchain, and the coming year will be a period of exponential growth for the company as they penetrate new industrial markets," says Kemal Farid, partner at L37, in the release. "We believe strongly that GumboNet will become the de facto network for smart contracts across industries for capturing value and solving enormous pain points in contractual relations. Additionally, as companies move to meet increasing sustainability measurement demands and ESG improvements, there is a huge growth path available for Data Gumbo with the launch of GumboNet ESG."

Earlier this year, the company announced its environmental, social and corporate governance tracking and reporting tool.

"Equinor's recent pilot at the Johan Sverdrup field has demonstrated that GumboNet can create strong value for the partnership," says Gareth Burns, head of Equinor Ventures, in the release. "Our follow-on investment confirms Equinor Ventures' confidence in Data Gumbo's solution for our company and the broader energy industry."

Trending News